GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-13 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
=== Designed nucleic acid systems === Scientists can encode digital information onto a single strand of synthetic DNA. In 2012, George M. Church encoded one of his books about synthetic biology in DNA. The 5.3 Mb of data was more than 1000 times greater than the previous largest amount of information to be stored in synthesized DNA. A similar project encoded the complete sonnets of William Shakespeare in DNA. More generally, algorithms such as NUPACK, ViennaRNA, Ribosome Binding Site Calculator, Cello, and Non-Repetitive Parts Calculator enables the design of new genetic systems. Many technologies have been developed for incorporating unnatural nucleotides and amino acids into nucleic acids and proteins, both in vitro and in vivo. For example, in May 2014, researchers announced that they had successfully introduced two new artificial nucleotides into bacterial DNA. By including individual artificial nucleotides in the culture media, they were able to exchange the bacteria 24 times; they did not generate mRNA or proteins able to use the artificial nucleotides.
=== Diagnosis === The assessment of vitamin B6 status is essential, as the clinical signs and symptoms in less severe cases are not specific. The three biochemical tests most widely used are plasma PLP concentrations, the activation coefficient for the erythrocyte enzyme aspartate aminotransferase, and the urinary excretion of vitamin B6 degradation products, specifically urinary PA. Of these, plasma PLP is probably the best single measure, because it reflects tissue stores. Plasma PLP of less than 10 nmol/L is indicative of vitamin B6 deficiency. A PLP concentration greater than 20 nmol/L has been chosen as a level of adequacy for establishing Estimated Average Requirements and Recommended Daily Allowances in the USA. Urinary PA is also an indicator of vitamin B6 deficiency; levels of less than 3.0 mmol/day is suggestive of vitamin B6 deficiency. Other methods of measurement, including UV spectrometric, spectrofluorimetric, mass spectrometric, thin-layer and high-performance liquid chromatographic, electrophoretic, electrochemical, and enzymatic, have been developed. The classic clinical symptoms for vitamin B6 deficiency are rare, even in developing countries. A handful of cases were seen between 1952 and 1953, particularly in the United States, having occurred in a small percentage of infants who were fed a formula lacking in pyridoxine.
== Safety == Inhalation of n-hexane at 5000 ppm for 10 minutes produces marked vertigo; 2500-1000 ppm for 12 hours produces drowsiness, fatigue, loss of appetite, and paresthesia in the distal extremities; 2500–5000 ppm produces muscle weakness, cold pulsation in the extremities, blurred vision, headache, and anorexia. Chronic occupational exposure to elevated levels of n-hexane has been demonstrated to be associated with peripheral neuropathy in auto mechanics in the US, and neurotoxicity in workers in printing presses, and shoe and furniture factories in Asia, Europe, and North America. The US National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) for hexane isomers (not n-hexane) of 100 ppm (350 mg/m3 (0.15 gr/cu ft)) over an 8-hour workday. However, for n-hexane, the current NIOSH REL is 50 ppm (180 mg/m3 (0.079 gr/cu ft)) over an 8-hour workday. This limit was proposed as a permissible exposure limit (PEL) by the Occupational Safety and Health Administration in 1989; however, this PEL was overruled in US courts in 1992. The current n-hexane PEL in the US is 500 ppm (1,800 mg/m3 (0.79 gr/cu ft)). Hexane and other volatile hydrocarbons (petroleum ether) present an aspiration risk. n-Hexane is sometimes used as a denaturant for alcohol, and as a cleaning agent in the textile, furniture, and leather industries. It is slowly being replaced with other solvents. Like gasoline, hexane is highly volatile and is an explosion risk.
Sources: en.wikipedia.org
=== Video games === In April 2026, Austin was revealed to be added to Fortnite. He is the sixth WWE outfit added to the game following -- John Cena, Becky Lynch, Bianca Belair, Cody Rhodes and The Undertaker. Dwayne Johnson appears in the game but not as himself or The Rock but in an acting role using his likeness for the character The Foundation.
National Fireproofing Contractors Association https://www.nfca-online.org/ Structural Fire Protection - American Institute of Steel Construction https://www.aisc.org/globalassets/modern-steel/archives/2002/12/2002v12_fire.pdf NFPA Standards Archived 2011-07-28 at the Wayback Machine
==== MeSH D13.444.735 – rna ==== MeSH D13.444.735.130 – rna, algal MeSH D13.444.735.150 – rna, antisense MeSH D13.444.735.150.319 – micrornas MeSH D13.444.735.150.640 – oligoribonucleotides, antisense MeSH D13.444.735.150.700 – rna, small interfering MeSH D13.444.735.300 – rna, archaeal MeSH D13.444.735.473 – rna, bacterial MeSH D13.444.735.476 – rna, chloroplast MeSH D13.444.735.480 – rna, complementary MeSH D13.444.735.490 – rna, double-stranded MeSH D13.444.735.500 – rna, fungal MeSH D13.444.735.520 – rna, helminth MeSH D13.444.735.544 – rna, messenger MeSH D13.444.735.544.355 – codon MeSH D13.444.735.544.355.225 – codon, initiator MeSH D13.444.735.544.355.250 – codon, terminator MeSH D13.444.735.544.355.250.235 – codon, nonsense MeSH D13.444.735.544.500 – rna caps MeSH D13.444.735.544.500.710 – rna cap analogs MeSH D13.444.735.544.527 – rna, messenger, stored MeSH D13.444.735.544.550 – rna splice sites MeSH D13.444.735.544.875 – untranslated regions MeSH D13.444.735.544.875.880 – 3' untranslated regions MeSH D13.444.735.544.875.885 – 5' untranslated regions MeSH D13.444.735.615 – rna, neoplasm MeSH D13.444.735.628 – rna, nuclear MeSH D13.444.735.628.806 – rna, heterogeneous nuclear MeSH D13.444.735.628.818 – rna, small nuclear MeSH D13.444.735.628.818.800 – rna, small nucleolar MeSH D13.444.735.635 – rna, plant MeSH D13.444.735.635.575 – rna, chloroplast MeSH D13.444.735.640 – rna precursors MeSH D13.444.735.650 – rna, protozoan MeSH D13.444.735.686 – rna, ribosomal MeSH D13.444.735.686.650 – rna, ribosomal, 5s MeSH D13.444.735.686.660 – rna, ribosomal, 5.8s MeSH D13.444.735.686.670 – rna, ribosomal, 16s MeSH D13.444.735.686.675 – rna, ribosomal, 18s MeSH D13.444.735.686.680 – rna, ribosomal, 23s MeSH D13.444.735.686.690 – rna, ribosomal, 28s MeSH D13.444.735.686.845 – rna, ribosomal, self-splicing MeSH D13.444.735.721 – rna, satellite MeSH D13.444.735.721.250 – cucumber mosaic virus satellite MeSH D13.444.735.757 – rna, transfer MeSH D13.444.735.757.286 – anticodon MeSH D13.444.735.757.700 – rna, transfer, amino acid-specific MeSH D13.444.735.757.700.050 – rna, transfer, ala MeSH D13.444.735.757.700.075 – rna, transfer, arg MeSH D13.444.735.757.700.085 – rna, transfer, asn MeSH D13.444.735.757.700.090 – rna, transfer, asp MeSH D13.444.735.757.700.200 – rna, transfer, cys MeSH D13.444.735.757.700.400 – rna, transfer, gln MeSH D13.444.735.757.700.410 – rna, transfer, glu MeSH D13.444.735.757.700.420 – rna, transfer, gly MeSH D13.444.735.757.700.450 – rna, transfer, his MeSH D13.444.735.757.700.480 – rna, transfer, ile MeSH D13.444.735.757.700.500 – rna, transfer, leu MeSH D13.444.735.757.700.510 – rna, transfer, lys MeSH D13.444.735.757.700.525 – rna, transfer, met MeSH D13.444.735.757.700.650 – rna, transfer, phe MeSH D13.444.735.757.700.660 – rna, transfer, pro MeSH D13.444.735.757.700.700 – rna, transfer, ser MeSH D13.444.735.757.700.725 – rna, transfer, thr MeSH D13.444.735.757.700.740 – rna, transfer, trp MeSH D13.444.735.757.700.750 – rna, transfer, tyr MeSH D13.444.735.757.700.900 – rna, transfer, val MeSH D13.444.735.757.715 – rna, transfer, amino acyl MeSH D13.444.735.790 – rna, untranslated MeSH D13.444.735.790.099 – micrornas MeSH D13.444.735.790.149 – regulatory sequences, ribonucleic acid MeSH D13.444.735.790.199 – rna, catalytic MeSH D13.444.735.790.400 – rna, guide MeSH D13.444.735.790.530 – rna, small cytoplasmic MeSH D13.444.735.790.537 – rna, small interfering MeSH D13.444.735.790.545 – rna, small nuclear MeSH D13.444.735.790.545.800 – rna, small nucleolar MeSH D13.444.735.790.560 – rna, spliced leader MeSH D13.444.735.790.878 – untranslated regions MeSH D13.444.735.790.878.880 – 3' untranslated regions MeSH D13.444.735.790.878.885 – 5' untranslated regions MeSH D13.444.735.828 – rna, viral
Sources: en.wikipedia.org
The GTP-binding domain is conserved in both EF-1alpha/EF-Tu and also in EF-2/EF-G and thus seems typical for GTP-dependent proteins which bind non-initiator tRNAs to the ribosome. The GTP-binding translation factor family also includes the eukaryotic peptide chain release factor GTP-binding subunits and prokaryotic peptide chain release factor 3 (RF-3); the prokaryotic GTP-binding protein lepA and its homologue in yeast (GUF1) and Caenorhabditis elegans (ZK1236.1); yeast HBS1; rat Eef1a1 (formerly "statin S1"); and the prokaryotic selenocysteine-specific elongation factor selB.
An immediate ceasefire. The withdrawal of MNLA and HCUA forces to designated cantonment sites, primarily around Kidal. The deployment of the Malian army to Kidal to secure the elections. The formation of a joint commission, comprising the Malian army, rebel groups, French forces, and the United Nations Multidimensional Integrated Stabilization Mission in Mali (MINUSMA), to oversee the implementation of security measures. The inclusion of the term "Azawad" in the agreement, despite opposition from Bamako. Although the Malian government initially demanded the disarmament of the MNLA, this condition was waived in exchange for the rebels allowing the Malian army back into Kidal. Furthermore, the MNLA and HCUA did not secure an amnesty for their leaders, many of whom remained under international arrest warrants.
Gastrointestinal: constipation, diarrhea, nausea, vomiting Dermatologic: erythema, pain, phlebitis, rash Neurologic: headaches, insomnia Prolonged periods of piperacillin-tazobactam therapy have been associated with the potential development of hematologic adversities such as leukopenia (16.3%), neutropenia (10%), and eosinophilia (10%) in adult patients. The combination of piperacillin-tazobactam with other antibiotics was found to be a major risk factor for leukopenia as well. Additionally, the chances of developing these illnesses increases in younger patients with fewer conditions, prolonging their time to recover. Other cases of adverse effects include instances of renal dysfunction, hepatitis, hyperactivity, anemia, abnormalities in coagulation, and hypokalemia. Allergic reactions can be induced from the side chains of β-lactam antibiotics such as amoxicillin, or antibodies surrounding the nucleus of penicillin.
== Signs and symptoms == Skin: The pigment is deposited throughout the skin, but only becomes apparent in certain locations, where the concentration is great enough to be seen clinically. This usually occurs in areas where connective tissue is thick (joints, tympanic membrane) or close to the surface of the skin (thenar and hypothenar eminences and the sides of the fingers). In exogenous ochronosis, the hyperpigmentation is localized to the area where the inciting agent is applied. Intradermal nevi can appear like blue nevi. Eye: Ocular manifestations are frequent in patients with ochronosis; most commonly hyperpigmentation of the sclera, primarily observed symmetrically to both sides of the cornea within the palpebral fissure. Furthermore, brown pigment spots in the limbus are generally considered pathognomonic. These ocular signs generally occur early in the development of the disease and can serve as a valuable diagnostic feature of the disease. Cartilage: Darkening and hardening of ear cartilage is a prominent feature of ochronosis. Nasal cartilage is also frequently involved. The voice can be affected by hardening of the laryngeal cartilage. Stiffening of the ribs with decreased lung function has also been reported. The intervertebral cartilage is also more prone to herniation. Connective tissue: Hardening of tendons and ligaments can predispose them to rupture. Color changes in the joints can be observed clinically. Arthropathy is common due to chronic inflammation and microruptures.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.